{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06378346",
            "orgStudyIdInfo": {
                "id": "2023-077"
            },
            "organization": {
                "fullName": "University of Illinois at Chicago",
                "class": "OTHER"
            },
            "briefTitle": "GU-01: Glycyrrhizin in Prostate Cancer",
            "officialTitle": "GU-01: Glycyrrhizin in Prostate Cancer: A Window-of-Opportunity Trial",
            "acronym": "GU-01",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "gu-glycyrrhizin-in-prostate-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-07",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-03",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-03",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-04-18",
            "studyFirstSubmitQcDate": "2024-04-18",
            "studyFirstPostDateStruct": {
                "date": "2024-04-22",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-24",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-26",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Natalie Reizine",
                "investigatorTitle": "Principal Investigator",
                "investigatorAffiliation": "University of Illinois at Chicago"
            },
            "leadSponsor": {
                "name": "University of Illinois at Chicago",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a pilot, randomized, window-of-opportunity treatment trial in which participants with previously untreated prostate cancer (PCa) who are candidates for surgery (radical prostatectomy)",
            "detailedDescription": "This is a pilot, randomized, window-of-opportunity treatment trial in which participants with previously untreated prostate cancer who are candidates for surgery (radical prostatectomy) will receive one cycle of therapy consisting of Glycyrrhizin (GLY) (Observation, Dose Level 1 75mg daily, or Dose Level 2, 150mg daily) for 6 weeks (+/- 2 weeks) prior to surgery."
        },
        "conditionsModule": {
            "conditions": [
                "Prostate Cancer"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 60,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Observational Arm 1",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "10 participants will be randomized to observational arm",
                    "interventionNames": [
                        "Other: Glycyrrhizin",
                        "Other: Observation"
                    ]
                },
                {
                    "label": "Glycyrrhizin Arm 2",
                    "type": "EXPERIMENTAL",
                    "description": "25 participants will be randomized to receive 75mg daily for 6 weeks (+/- 2 weeks)",
                    "interventionNames": [
                        "Drug: Glycyrrhizin"
                    ]
                },
                {
                    "label": "Glycyrrhizin Arm 3",
                    "type": "EXPERIMENTAL",
                    "description": "25 participants will be randomized to receive 150mg daily for 6 weeks (+/- 2 weeks)",
                    "interventionNames": [
                        "Drug: Glycyrrhizin"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Glycyrrhizin",
                    "description": "75mg orally daily",
                    "armGroupLabels": [
                        "Glycyrrhizin Arm 2",
                        "Glycyrrhizin Arm 3"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Glycyrrhizin",
                    "description": "150mg orally daily",
                    "armGroupLabels": [
                        "Observational Arm 1"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Observation",
                    "description": "Participants will not receive any Glycyrrhizin",
                    "armGroupLabels": [
                        "Observational Arm 1"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of participants that have a change in prostate-specific antigen (PSA) before GLY administration",
                    "description": "To evaluate the anti-tumor activity of GLY as assessed by change in PSA before GLY administration",
                    "timeFrame": "2 months"
                },
                {
                    "measure": "Number of participants that have a change in prostate-specific antigen (PSA) after GLY administration and prior to radical prostatectomy",
                    "description": "To evaluate the anti-tumor activity of GLY as assessed by change in PSA after GLY administration and prior to radical prostatectomy",
                    "timeFrame": "2 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "The tolerability of GLY will be assessed by NCI Common Terminology Criteria for Adverse Events (AE) (NCI CTCAE) Version 5 (v5.0).",
                    "description": "The safety rate is calculated as the proportion of patients without Grade 2 or higher AE.",
                    "timeFrame": "2 months"
                },
                {
                    "measure": "Assessment of plasma GLY levels after GLY administration",
                    "description": "The number of participants that have plasma GLY levels after administration of GLY",
                    "timeFrame": "2 months"
                },
                {
                    "measure": "Assessment of blood sodium levels after GLY administration",
                    "description": "The number of participants that have sodium levels within normal limits (WNL)",
                    "timeFrame": "2 months"
                },
                {
                    "measure": "Assessment of blood potassium after GLY administration",
                    "description": "The number of participants that have potassium levels within normal limits (WNL)",
                    "timeFrame": "2 months"
                },
                {
                    "measure": "Assessment of serum creatinine after GLY administration",
                    "description": "The number of participants that have serum creatinine levels within normal limits (WNL)",
                    "timeFrame": "2 months"
                },
                {
                    "measure": "Assessment of serum testosterone levels after GLY administration",
                    "description": "Change in serum testosterone levels",
                    "timeFrame": "2 months"
                },
                {
                    "measure": "Assessment of serum dehydroepiandrosterone sulfate (DHEA-S) levels after GLY administration",
                    "description": "Change in serum dehydroepiandrosterone sulfate (DHEA-S) levels",
                    "timeFrame": "2 months"
                },
                {
                    "measure": "Assessment of interleukin-1\u03b2 (IL-1\u03b2) after GLY administration",
                    "description": "Change in interleukin-1\u03b2 (IL-1\u03b2) inflammatory marker",
                    "timeFrame": "2 months"
                },
                {
                    "measure": "Assessment of Tumor necrosis factor \u03b1 (TNF\u03b1) after GLY administration",
                    "description": "Change in Tumor necrosis factor \u03b1 (TNF\u03b1) inflammatory marker",
                    "timeFrame": "2 months"
                },
                {
                    "measure": "Assessment of interleukin 6 (IL-6) after GLY administration",
                    "description": "Change in interleukin 6 (IL-6) inflammatory marker",
                    "timeFrame": "2 months"
                },
                {
                    "measure": "Assessment of serum Vascular Endothelial Growth Factor (VEGF) after GLY administration",
                    "description": "Change in VEGF levels",
                    "timeFrame": "2 months"
                },
                {
                    "measure": "Assessment of Hepatocyte Growth Factor (HGF) after GLY",
                    "description": "Change in HGF levels",
                    "timeFrame": "2 months"
                },
                {
                    "measure": "Assessment of Insulin-like Growth Factor-1 (IGF-1) after GLY",
                    "description": "Change in IGF-1 levels",
                    "timeFrame": "2 months"
                },
                {
                    "measure": "Evaluate patient perspectives on clinical trial enrollment and complementary and integrative medicine (CAM) approaches as evaluated through survey questionnaires administered before GLY administration",
                    "description": "Number of participants that have positive results per survey questionaries",
                    "timeFrame": "2 months"
                },
                {
                    "measure": "Evaluate patient perspectives on clinical trial enrollment and complementary and integrative medicine (CAM) approaches as evaluated through survey questionnaires administered after GLY administration",
                    "description": "Number of participants that have positive results per survey questionaries",
                    "timeFrame": "2 months"
                },
                {
                    "measure": "Gene expression analysis in tumor specimens obtained before administration of GLY",
                    "description": "Gene expression analysis in tumor specimens obtained before administration of GLY",
                    "timeFrame": "2 months"
                },
                {
                    "measure": "Number of patients with changes in gene expression analysis in tumor specimens obtained after administration of GLY",
                    "description": "Gene expression analysis in tumor specimens obtained after administration of GLY",
                    "timeFrame": "2 months"
                },
                {
                    "measure": "Number of patients with changes to fasting serum glucose level before GLY administration",
                    "description": "Number of patients with changes to fasting serum glucose level before GLY administration",
                    "timeFrame": "2 months"
                },
                {
                    "measure": "Number of patients with changes to fasting serum glucose level after GLY administration",
                    "description": "Number of patients with changes to fasting serum glucose level after GLY administration",
                    "timeFrame": "2 months"
                },
                {
                    "measure": "Number of patients with changes to fasting serum insulin level before GLY administration",
                    "description": "Number of patients with changes to fasting serum insulin levelnbefore GLY administration",
                    "timeFrame": "2 months"
                },
                {
                    "measure": "Number of patients with changes to fasting serum insulin level after GLY administration",
                    "description": "Number of patients with changes to fasting serum insulin level after GLY administration",
                    "timeFrame": "2 months"
                },
                {
                    "measure": "Number of patients with changes to fasting serum lipid level before GLY administration",
                    "description": "Number of patients with changes to fasting serum lipid level before GLY administration",
                    "timeFrame": "2 months"
                },
                {
                    "measure": "Number of patients with changes to fasting serum lipid level after GLY administration",
                    "description": "Number of patients with changes to fasting serum lipid level after GLY administration",
                    "timeFrame": "2 months"
                },
                {
                    "measure": "Number of patients with C-Reactive Protein before GLY administration",
                    "description": "Number of patients with C-Reactive Protein before GLY administration",
                    "timeFrame": "2 months"
                },
                {
                    "measure": "Number of patients with concentration of GLY in tumor specimens before GLY administration",
                    "description": "Number of patients with concentration of GLY in tumor specimens before GLY administration",
                    "timeFrame": "2 months"
                },
                {
                    "measure": "Number of patients with concentration of GLY in tumor specimens after GLY administration",
                    "description": "Number of patients with concentration of GLY in tumor specimens after GLY administration",
                    "timeFrame": "2 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Age \u2265 18 years of age at time of consent\n2. ECOG performance status of 0, 1, or 2\n3. Histologic diagnosis of prostate cancer\n4. Patient suitable for radical prostatectomy as determined by surgical team\n5. Able to provide written informed consent and HIPAA authorization for release of personal health information, via an approved UIC Institutional Review Board (IRB) informed consent form and HIPAA authorization.\n6. Willing to use barrier contraceptive method during study intervention\n\nExclusion Criteria:\n\n1. Any prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of this investigational regimen, as determined by the treating urologic oncology team.\n2. Previous chemotherapy, biological therapy, radiation therapy, androgens, thalidomide, immunotherapy, other anticancer agents and/or investigational agents within 30 days of starting study treatment.\n3. Potent or moderate inhibitors and inducers of CYP3A4 if taken within a 1 week wash-out period\n4. Concomitant medications known to prolong QT interval, or with factors that increase the risk of QTc prolongation, or History of Torsades de Pointes. This may include patients who have sub-optimally controlled hypertension, serum potassium levels \\<4.0 mEq/L, serum magnesium \u22641.8 mg/dL, prolonged gastrointestinal transit time, or decreased 11-\u03b2-hydroxysteriod dehydrogenase-2 activity.",
            "healthyVolunteers": false,
            "sex": "MALE",
            "genderBased": true,
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Natalie Reizine, MD",
                    "role": "CONTACT",
                    "phone": "312-996-1581",
                    "email": "nreizi2@uic.edu"
                },
                {
                    "name": "Omer Qazi, MBBS",
                    "role": "CONTACT",
                    "phone": "312-413-1069",
                    "email": "omerqazi@uic.edu"
                }
            ],
            "locations": [
                {
                    "facility": "University of Illinois",
                    "status": "RECRUITING",
                    "city": "Chicago",
                    "state": "Illinois",
                    "zip": "60612",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Natalie Reizine, MD",
                            "role": "CONTACT",
                            "phone": "312-996-1581",
                            "email": "nreizi2@uic.edu"
                        },
                        {
                            "name": "Omer Qazi, MBBS",
                            "role": "CONTACT",
                            "phone": "312-413-1069",
                            "email": "omerqazi@uic.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.85003,
                        "lon": -87.65005
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011471",
                    "term": "Prostatic Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000005834",
                    "term": "Genital Neoplasms, Male"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000005832",
                    "term": "Genital Diseases, Male"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000011469",
                    "term": "Prostatic Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14335",
                    "name": "Prostatic Neoplasms",
                    "asFound": "Prostate Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8946",
                    "name": "Genital Neoplasms, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8944",
                    "name": "Genital Diseases, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14333",
                    "name": "Prostatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000019695",
                    "term": "Glycyrrhizic Acid"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000893",
                    "term": "Anti-Inflammatory Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M21610",
                    "name": "Glycyrrhizic Acid",
                    "asFound": "Contact lens solution",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4217",
                    "name": "Anti-Inflammatory Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infl",
                    "name": "Anti-Inflammatory Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}